Inactive Instrument

Press Releases Arcturus Therapeutics Ltd Nasdaq

Equities

IL0011280240

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 8, 2024	Apr. 25	BU
Arcturus Therapeutics : Positive Results of Phase III Study of Bivalent Version of Kostaive®, Self-Amplifying mRNA Vaccine Against COVID-19 (Ancestral Strain and Omicron BA.4/5), for Booster Vaccination Conducted in Japan - Form 8-K	Mar. 19	PU
Arcturus Therapeutics: Q4 Earnings Snapshot	Mar. 07	AQ
Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2023 Financial Update and Pipeline Progress	Mar. 07	BU
Arcturus Therapeutics to Present at the Barclays 26th Annual Global Healthcare Conference	Feb. 26	BU
Arcturus Therapeutics Receives Orphan Medicinal Product Designation from the European Commission, for ARCT-032, for the Treatment of Cystic Fibrosis	Feb. 23	AQ
Arcturus Therapeutics Receives Orphan Medicinal Product Designation from the European Commission (EC), for ARCT-032, for the Treatment of Cystic Fibrosis	Feb. 22	BU
Arcturus Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update on March 7, 2024	Feb. 20	BU
New COVID-19 sa-mRNA Results from CSL and Arcturus Therapeutics Demonstrate Longer Duration of Immunity Compared to Conventional COVID-19 mRNA Vaccine Booster	Feb. 05	BU
New COVID-19 sa-mRNA Results from CSL and Arcturus Therapeutics Demonstrate Longer Duration of Immunity Compared to Conventional COVID-19 mRNA Vaccine Booster	Feb. 05	PR
CSL and Arcturus Therapeutics ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicron BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster	Dec. 22	AQ
CSL and Arcturus Therapeutics’ ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicron BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster	Dec. 21	BU
CSL and Arcturus Therapeutics' ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicron BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster	Dec. 21	PR
Arcturus Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference	Dec. 04	BU
Japan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics ARCT-154, the First Self-Amplifying mRNA Vaccine Approved for COVID in Adults	Nov. 29	AQ
Japan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics’ ARCT-154, the First Self-Amplifying mRNA Vaccine Approved for COVID in Adults	Nov. 28	BU
Japan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics' ARCT-154, the first Self-Amplifying mRNA vaccine approved for COVID in adults	Nov. 28	PR
Arcturus Therapeutics Receives Orphan Drug Designation from the U.S. FDA for ARCT-032, for the Treatment of Cystic Fibrosis	Nov. 27	BU
Arcturus Therapeutics: Q3 Earnings Snapshot	Nov. 14	AQ
Arcturus Therapeutics Announces Third Quarter 2023 Financial Update and Pipeline Progress	Nov. 14	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Arcturus Therapeutics Ltd Nasdaq

Equities

IL0011280240

Press Releases

Filters